NASDAQ:ABVX Abivax (ABVX) Stock Price, News & Analysis $71.94 +0.17 (+0.24%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$72.68 +0.73 (+1.02%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Abivax Stock (NASDAQ:ABVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Abivax alerts:Sign Up Key Stats Today's Range$69.37▼$72.9550-Day Range$5.67▼$71.9452-Week Range$4.77▼$75.51Volume1.25 million shsAverage Volume3.08 million shsMarket Capitalization$4.57 billionP/E RatioN/ADividend YieldN/APrice Target$92.33Consensus RatingBuy Company Overview ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France. Read More Abivax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreABVX MarketRank™: Abivax scored higher than 72% of companies evaluated by MarketBeat, and ranked 258th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingAbivax has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbivax has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abivax's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Abivax are expected to grow in the coming year, from ($2.83) to ($2.57) per share.Price to Book Value per Share RatioAbivax has a P/B Ratio of 104.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abivax's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.57% of the float of Abivax has been sold short.Short Interest Ratio / Days to CoverAbivax has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abivax has recently decreased by 4.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbivax does not currently pay a dividend.Dividend GrowthAbivax does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.57% of the float of Abivax has been sold short.Short Interest Ratio / Days to CoverAbivax has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abivax has recently decreased by 4.03%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment0.31 News SentimentAbivax has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Abivax this week, compared to 2 articles on an average week.Search Interest30 people have searched for ABVX on MarketBeat in the last 30 days. This is an increase of 2,900% compared to the previous 30 days.MarketBeat Follows8 people have added Abivax to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Abivax insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abivax's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abivax and its competitors with MarketBeat's FREE daily newsletter. Email Address ABVX Stock News HeadlinesJMP Securities Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)August 2 at 3:24 AM | theglobeandmail.comPiper Sandler Reaffirms Their Buy Rating on Abivax SA Sponsored ADR (ABVX)August 2 at 3:24 AM | theglobeandmail.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.August 2 at 2:00 AM | The Oxford Club (Ad)Piper Sandler Raised the Firm’s PT on ABIVAX Société (ABVX), Kept an Overweight RatingAugust 2 at 3:24 AM | msn.comPiper Sandler Raises Price Target for Abivax (ABVX)August 1 at 2:45 AM | msn.comThis Stock Is Up by 800% This Year -- but Is It a Buy?July 31 at 8:44 PM | msn.comAbivax (NASDAQ:ABVX) Trading Up 5.2% on Analyst UpgradeJuly 31 at 2:48 AM | americanbankingnews.comAbivax price target raised to $112 from $70 at Piper SandlerJuly 30 at 5:49 AM | msn.comSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? Abivax's stock was trading at $7.32 at the start of the year. Since then, ABVX stock has increased by 882.8% and is now trading at $71.94. When did Abivax IPO? Abivax (ABVX) raised $217 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60 per share. How do I buy shares of Abivax? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abivax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abivax investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), G1 Therapeutics (GTHX), Howard Hughes (HHH) and KT (KT). Company Calendar Today8/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Price Target for Abivax$92.33 High Price Target$112.00 Low Price Target$71.00 Potential Upside/Downside+28.3%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.29 Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book104.26Miscellaneous Outstanding Shares63,470,000Free FloatN/AMarket Cap$4.57 billion OptionableNot Optionable Beta0.33 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ABVX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.